AR054890A1 - Derivados de quinolina como agentes antibacterianos - Google Patents
Derivados de quinolina como agentes antibacterianosInfo
- Publication number
- AR054890A1 AR054890A1 ARP060103372A ARP060103372A AR054890A1 AR 054890 A1 AR054890 A1 AR 054890A1 AR P060103372 A ARP060103372 A AR P060103372A AR P060103372 A ARP060103372 A AR P060103372A AR 054890 A1 AR054890 A1 AR 054890A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- hydrogen
- hydroxy
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Abstract
El uso de un compuesto para la fabricacion de un medicamento para el tratamiento de una infeccion bacteriana siempre y cuando la infeccion bacteriana no sea una infeccion microbacteriana, siendo dicho compuesto un compuesto de formula (1), una sal adicion o de base farmacéutica aceptable, una amina cuaternaria, una forma estereoquímicamente isomérica, una forma tautomérica o una forma N-oxido del mismo, donde R1 es hidrogeno, halo, haloalquilo, ciano, hidroxi, Ar, Het, alquilo, alquiloxi, alquiltio, alquiloxialquilo, alquiltioalquilo, Ar-alquilo o di(Ar)alquilo; p es 1 a 3; s es 0 a 4; R2 es hidrogeno; halo; alquilo; hidroxi; mercapto; alquiloxi opcionalmente sustituido; alquiloxialquiloxi; alquiltio; mono o di(alquil)amino donde alquilo puede estar opcionalmente sustituido; Ar; Het o un radical de formula (2); R3 es alquilo, Ar, Ar-alquilo, Het o Het-alquilo; q es 0 a 4; R4 y R5 son cada uno independientemente hidrogeno, alquilo o bencilo; o R4 y R5 pueden tomarse en conjunto incluyendo el N al cual están ligados; R6 es hidrogeno, halo, haloalquilo, hidroxi, Ar, alquilo, alquiloxi, alquiltio, alquiloxialquilo, alquiltioalquilo, Ar-alquilo o di(Ar)alquilo; o dos radicales R6 vecinos pueden tomarse en conjunto para formar junto con el anillo fenilo al cual están ligados un naftilo; r es 1 a 5; R7 es hidrogeno, alquilo, Ar o Het; R8 es hidrogeno, alquilo, hidroxilo, aminocarbonilo, mono- o di(alquil)aminocarbonilo, Ar, Het, alquilo sustituido con uno o dos Het, alquilo sustituido con uno o dos Ar, Het-C(=O)- o Ar-C(=O)-; siempre que cuando el radical que soporta a R3 esté colocado en la posicion 3 de la porcion quinolina; R7 esté colocado en la posicion 4 y R2 esté colocado en la posicion 2 y represente hidrogeno, hidroxi, mercapto, alquiloxi, alquiloxialquiloxi, alquiltio, mono o di(alquil)amino o un radical de formula (3), entonces s es 1 a 4. Reivindicacion 16: Proceso para la preparacion de un compuesto de formula (4), caracterizado por hacer reaccionar un intermediario de formula (5) donde q' es 0, 1 o 2, con una amina primaria o secundaria NHR4R5 en presencia de un catalizador adecuado, opcionalmente en presencia de un segundo catalizador, en presencia de un ligando adecuado, un solvente adecuado y en presencia de CO y H2 (bajo presion) a temperatura elevada con R1, R2, R3, R4, R5, R6, R7, p, s y r como se definio en la reivindicacion 1. Reivindicacion 17: Un compuesto seleccionado entre las formulas (6) o (7), una sal de adicion de ácido o de base farmacéuticamente aceptable del mismo, una amina cuaternaria del mismo, una forma estereoquímicamente isomérica del mismo, una forma tautomérica del mismo o una forma N-oxido del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107164 | 2005-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054890A1 true AR054890A1 (es) | 2007-07-25 |
Family
ID=35744723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103372A AR054890A1 (es) | 2005-08-03 | 2006-08-02 | Derivados de quinolina como agentes antibacterianos |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8802671B2 (es) |
| EP (1) | EP1912648B1 (es) |
| JP (1) | JP5302680B2 (es) |
| KR (1) | KR101413997B1 (es) |
| CN (2) | CN101277696B8 (es) |
| AP (1) | AP2654A (es) |
| AR (1) | AR054890A1 (es) |
| AU (1) | AU2006274880B2 (es) |
| BR (1) | BRPI0614493B8 (es) |
| CA (1) | CA2615903C (es) |
| CY (1) | CY1114318T1 (es) |
| DK (1) | DK1912648T3 (es) |
| EA (1) | EA014833B1 (es) |
| ES (1) | ES2414956T3 (es) |
| HK (1) | HK1124234A1 (es) |
| HR (1) | HRP20130540T1 (es) |
| IL (1) | IL189142A0 (es) |
| JO (1) | JO2855B1 (es) |
| ME (1) | ME01616B (es) |
| MX (1) | MX2008001603A (es) |
| MY (1) | MY159560A (es) |
| NO (1) | NO341242B1 (es) |
| NZ (1) | NZ565947A (es) |
| PL (1) | PL1912648T3 (es) |
| PT (1) | PT1912648E (es) |
| RS (1) | RS52808B (es) |
| SI (1) | SI1912648T1 (es) |
| TW (1) | TWI422374B (es) |
| UA (1) | UA95915C2 (es) |
| WO (1) | WO2007014941A2 (es) |
| ZA (1) | ZA200801110B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004186452A (ja) | 2002-12-04 | 2004-07-02 | Renesas Technology Corp | 不揮発性半導体記憶装置およびその製造方法 |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| KR20150070348A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
| PL2909192T3 (pl) | 2012-10-16 | 2017-09-29 | Janssen Pharmaceutica Nv | Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| WO2015057629A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | ALKYL LINKED QUINOLINYL MODULATORS OF RORyt |
| CN109111396B (zh) * | 2018-08-28 | 2021-09-03 | 广东工业大学 | 一种喹啉芳香乙烯衍生物及其制备方法和应用 |
| CN109111397B (zh) * | 2018-08-28 | 2021-12-10 | 广东工业大学 | 一种喹啉芳香乙烯类衍生物及其制备方法和应用 |
| CN112110907B (zh) * | 2020-10-09 | 2021-12-21 | 中央民族大学 | 一种含1，4-二氧六环二聚双噻吩结构的化合物及其制备方法和应用 |
| CN112079825B (zh) * | 2020-10-09 | 2021-12-21 | 中央民族大学 | 含1，3-二氧戊环二聚双噻吩结构的化合物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB807750A (en) * | 1956-06-15 | 1959-01-21 | Rhone Poulenc Sa | Improvements in or relating to piperazine derivatives |
| GB9317491D0 (en) * | 1993-08-23 | 1993-10-06 | Fujisawa Pharmaceutical Co | New compound and a process for preparation thereof |
| CA2270123A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
| PT2301544E (pt) * | 2002-07-25 | 2012-12-10 | Janssen Pharmaceutica Nv | Novos inibidores de micobactérias |
| PL360102A3 (en) | 2003-05-13 | 2004-11-15 | "ENERGOMAR-NORD" Sp.z o.o. | Method for manufacturing highly reactive calcium sorbing agents and facility designed for manufacturing highly reactive calcium sorbing agents |
| UA85570C2 (uk) | 2004-01-23 | 2009-02-10 | Янссен Фармацевтика Н.В. | Заміщені хіноліни та їх застосування як мікобактеріальних інгібіторів |
| RS51074B (sr) | 2004-01-23 | 2010-10-31 | Janssen Pharmaceutica N.V. | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora |
| AP2321A (en) * | 2004-01-29 | 2011-11-16 | Janssen Pharmaceutica Nv | Quinoline derivatives for use as mycobactrial inhibitor. |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| US20070018948A1 (en) | 2005-07-22 | 2007-01-25 | Elaine Chen | Apparatus for stabilizing an electronic device during data input and device control |
-
2006
- 2006-07-18 JO JO2006232A patent/JO2855B1/en active
- 2006-07-31 DK DK06778083.3T patent/DK1912648T3/da active
- 2006-07-31 PL PL06778083T patent/PL1912648T3/pl unknown
- 2006-07-31 EA EA200800508A patent/EA014833B1/ru unknown
- 2006-07-31 ES ES06778083T patent/ES2414956T3/es active Active
- 2006-07-31 MX MX2008001603A patent/MX2008001603A/es active IP Right Grant
- 2006-07-31 RS RS20130254A patent/RS52808B/en unknown
- 2006-07-31 UA UAA200801432A patent/UA95915C2/ru unknown
- 2006-07-31 NZ NZ565947A patent/NZ565947A/en not_active IP Right Cessation
- 2006-07-31 WO PCT/EP2006/064858 patent/WO2007014941A2/en active Application Filing
- 2006-07-31 ME MEP-2013-65A patent/ME01616B/me unknown
- 2006-07-31 JP JP2008524509A patent/JP5302680B2/ja active Active
- 2006-07-31 AP AP2008004316A patent/AP2654A/xx active
- 2006-07-31 SI SI200631602T patent/SI1912648T1/sl unknown
- 2006-07-31 US US11/997,173 patent/US8802671B2/en active Active
- 2006-07-31 PT PT67780833T patent/PT1912648E/pt unknown
- 2006-07-31 AU AU2006274880A patent/AU2006274880B2/en not_active Ceased
- 2006-07-31 CA CA2615903A patent/CA2615903C/en active Active
- 2006-07-31 KR KR1020087005071A patent/KR101413997B1/ko active IP Right Grant
- 2006-07-31 CN CN200680036751.2D patent/CN101277696B8/zh active Active
- 2006-07-31 BR BRPI0614493A patent/BRPI0614493B8/pt not_active IP Right Cessation
- 2006-07-31 EP EP06778083.3A patent/EP1912648B1/en active Active
- 2006-07-31 CN CNA2006800367512A patent/CN101277696A/zh active Granted
- 2006-08-01 MY MYPI20063727A patent/MY159560A/en unknown
- 2006-08-02 TW TW095128224A patent/TWI422374B/zh active
- 2006-08-02 AR ARP060103372A patent/AR054890A1/es unknown
-
2008
- 2008-01-31 IL IL189142A patent/IL189142A0/en active IP Right Grant
- 2008-02-01 ZA ZA2008/01110A patent/ZA200801110B/en unknown
- 2008-02-27 NO NO20081026A patent/NO341242B1/no not_active IP Right Cessation
-
2009
- 2009-02-05 HK HK09101045.4A patent/HK1124234A1/zh not_active IP Right Cessation
-
2013
- 2013-06-14 HR HRP20130540TT patent/HRP20130540T1/hr unknown
- 2013-07-09 CY CY20131100578T patent/CY1114318T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| TR200103497T2 (tr) | Beta2-adrenoseptör agonistler. | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| AR088235A1 (es) | Derivados de pirazoloquinolina | |
| AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
| CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
| HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| AR056418A1 (es) | Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento | |
| ATE514698T1 (de) | Tetracyclische azapyrazinoindoline als 5-ht2- liganden | |
| AR054888A1 (es) | Derivados de quinolina como agentes antibacterianos | |
| AR054103A1 (es) | Sales de amino de 1,2,3-triazoles, composiciones farmaceuticas que las contienen y usos como agentes antivirales | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
| AR088414A1 (es) | Derivados sustituidos de indol | |
| EA200800152A1 (ru) | Производные хинолина в качестве антибактериальных агентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |